Overview

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to determine the safety & efficacy of ranibizumab for the treatment of retinal angiomatous proliferation secondary to age related macular degeneration.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

The National Retina Institute

Collaborator:

Genentech, Inc.

Treatments:

Ranibizumab